5α-androstane-3β,7β,17β-triol | 49644-03-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5α-androstane-3β,7β,17β-triol
• 英文别名: Jgd4N79M5A；(3S,5R,7S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,17-triol
• CAS: 49644-03-3
• 化学式: C₁₉H₃₂O₃
• 分子量: 308.461
• InChiKey: UFGLFVVFQFFPSV-ZWPGJAPDSA-N

物化性质

• 沸点：
  456.1±30.0 °C(Predicted)
• 密度：
  1.163±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  雄诺龙 生成 5α-androstane-3β,7β,17β-triol
  参考文献：
  名称：

  Bell,A.M. et al., Journal of the Chemical Society. Perkin transactions I, 1973, p. 2131 - 2136

  摘要：

  DOI：

文献信息

• Catalytic Oxidations of Steroid Substrates by Artificial Cytochrome P-450 Enzymes
  作者：Jerry Yang、Bartolo Gabriele、Sandro Belvedere、Ying Huang、Ronald Breslow

  DOI：10.1021/jo020174u

  日期：2002.7.1

  perform hydroxylations with substrate selectivity and regio- and stereoselectivity and high catalytic turnovers. The geometries of the catalyst/substrate complexes override intrinsic substrate reactivities, permitting attack on geometrically accessible saturated carbons of steroids in the presence of secondary carbinol groups and carbon-carbon double bonds, as in enzymatic reactions. Selective hydroxylations

  包含带有环糊精结合基团的锰-卟啉的催化剂能够以底物选择性，区域和立体选择性以及高催化转化率进行羟基化。催化剂/底物配合物的几何形状超越了固有的底物反应性，从而允许在存在仲甲醇基团和碳-碳双键的情况下，如在酶促反应中，攻击类固醇的几何可及的饱和碳。甾族碳9位的选择性羟基化特别实用。
• SYNTHESIS OF A SUBSTITUTED INDENE DERIVATIVE
  申请人：AQUINOX PHARMACEUTICALS (CANADA) INC.

  公开号：US20170204048A1

  公开（公告）日：2017-07-20

  This invention is directed to methods of preparing AQX-1125 having the formula: This invention is also directed to intermediates utilized in the methods of preparing AQX-1125.

  这项发明涉及制备具有分子式AQX-1125的方法。该发明还涉及用于制备AQX-1125的中间体。
• Compositions containing corticosteroids or analogues thereof and
  申请人：——

  公开号：US05387583A1

  公开（公告）日：1995-02-07

  3.beta.,17.beta.-androstenediol (".beta.AED") and 3.beta.,7.beta.,17.beta.-androstenetriol (".beta.AET") may be used to counteract the antiproliferative and immunosuppressive effects of hydrocortisone and other corticosteroids (i.e., to act as buffers to counteract the lymphosuppressive response to such steroids). .beta.AED and .beta.AET are steroids which mediate immune response to provide the body protection against immune down-regulation. A method for testing analogues of .beta.AED and .beta.AET to compare the effectiveness of such analogues as buffers of certain effects of hydrocortisone and other corticosteroids, including immune response and proliferative effects is described. Cytokines, including most particularly IL-3, are produced by addition of .beta.AET and .beta.AED and their analogues to the growth media of cell cultures of lymphatic cells.

  3.beta.,17.beta.-雄烯二醇（".beta.AED"）和3.beta.，7.beta.，17.beta.-雄烯三醇（".beta.AET"）可用于抵消氢化可的松和其他皮质类固醇的抗增殖和免疫抑制作用（即作为缓冲剂来抵消这些类固醇的淋巴抑制反应）。.beta.AED和.beta.AET是类固醇，介导免疫反应，为身体提供免疫下调保护。描述了一种测试.beta.AED和.beta.AET的类似物以比较这些类似物作为缓冲氢化可的松和其他皮质类固醇的某些效应（包括免疫反应和增殖效应）的有效性的方法。通过向淋巴细胞的细胞培养基中添加.beta.AET和.beta.AED及其类似物来产生细胞因子，包括尤其是IL-3。
• Immune modulation method using steroid compounds
  申请人：——

  公开号：US20030060425A1

  公开（公告）日：2003-03-27

  The invention provides compositions comprising formula 1 steroids, e.g., 16&agr;-bromo-3 &bgr;-hydroxy-5&agr;-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

  本发明提供了由式 1 类固醇（如 16&agr;-溴-3&bgr;-羟基-5&agr;-雄甾烷-17-酮半水合物）和一种或多种赋形剂组成的组合物，包括由含水量小于约 3% v/v 的液体制剂组成的组合物。这些组合物可用于制造改进的药物制剂。本发明还提供了类固醇化合物（如 16&agr;-溴-3&bgr;-羟基-5&agr;-雄甾烷-17-酮的类似物）的间歇给药方法和用于此类给药方案的组合物。本发明进一步提供了抑制病原体复制、改善与免疫失调相关的症状以及使用化合物调节受试者免疫反应的组合物和方法。本发明还提供了制造和使用这些免疫调节组合物和制剂的方法。
• Therapeutic treatment methods 2
  申请人：Reading L. Christopher

  公开号：US20050101581A1

  公开（公告）日：2005-05-12

  The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

  本发明涉及使用化合物来改善或治疗诸如囊性纤维化、中性粒细胞减少症或其他示例性疾病。可使用的示例化合物包括 3β-羟基-17β-氨基雄甾-5-烯、3β-羟基-16α-氟-17β-氨基雄甾-5-烯、3α-羟基-16α-氟-17β-氨基雄甾-5-烯、3β-羟基-16β-氟-17β-氨基雄甾-5-烯、1α,3β-二羟基-4α-氟-雄甾-5-烯-17-酮、1α,3β,17β-三羟基-4α-氟雄甾烷-5-烯、1β,3β-二羟基-6α-溴雄甾烷-5-烯、1α-氟-3β,12α-二羟基雄甾烷-5-烯-17-酮、1α-氟-3β,4α-二羟基雄甾烷-5-烯和 4α-氟-3β,6α,17β-三羟基雄甾烷。